{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:13:20Z","timestamp":1778494400635,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bayerisches Zentrum f\u00fcr Krebsforschung"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["545058105"],"award-info":[{"award-number":["545058105"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Peptide receptor radionuclide therapy (PRRT) with Lu-177-DOTATATE is an established treatment option for neuroendocrine tumors (NETs) and has been extended to other somatostatin receptor (SSTR)-expressing tumors. We aimed to determine its efficacy and safety profile in patients with advanced radioiodine-refractory differentiated thyroid carcinoma (DTC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seven radioiodine-refractory DTC patients undergoing at least two cycles of PRRT were included. Patients were subdivided into continuous treatment (defined as sequential application of PRRT; 5\/7 (71.4%)) vs. discontinuous treatment (with at least one-year PRRT-free interval; 2\/7 (28.6%)). Baseline SSTR PET was analyzed to determine patients\u2019 eligibility for PRRT. Response was assessed by tumor control as defined by stable (\u00b1\u200930.0%) or decreasing (\u2265\u200930.0%) total tumor volume (PET-derived TTV), thyroglobulin (Tg) and RECIST 1.1 criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SSTR PET showed discernible high uptake (maximum standardized uptake values, 10.4\u2009\u00b1\u20098.6) in metastases, in particular in the skeleton. Continuous PRRT showed variable tumor control (stable disease \/ response; TTV: 3\/5 (60.0%); Tg: 2\/5 (40.0%); RECIST 1.1: 3\/5 (60.0%)). All patients undergoing discontinuous PRRT exhibited concordant stable disease upon first follow-up and renewed tumor control upon reinitiating PRRT (RECIST 1.1; decreasing TTV and Tg levels). No Common Terminology Criteria for Adverse Events (CTCAE) Grade 3\u20135 events occured in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In advanced radioiodine-refractory DTC, PRRT may be beneficial even after treatment interruptions, without major side effects. Given the small cohort and retrospective design, further prospective studies are needed to optimize PRRT strategies in DTC, in particular in a rechallenge scenario.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11307-025-02053-w","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:32:09Z","timestamp":1759174329000},"page":"954-965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET\/CT in Patients with Advanced Differentiated Thyroid Carcinoma"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3175-952X","authenticated-orcid":false,"given":"Sophie Carina","family":"Kunte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera U.","family":"Wenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel T.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam","family":"Widjaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz Josef","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Schirrmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Spitzweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph J.","family":"Auernhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias J.","family":"Zacherl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"2053_CR1","doi-asserted-by":"crossref","unstructured":"Yamazaki H, Sugino K, Katoh R, et al (2024) Management of follicular thyroid carcinoma. Eur Thyroid J 13(5):e240146","DOI":"10.1530\/ETJ-24-0146"},{"key":"2053_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1089\/thy.2021.0662","volume":"32","author":"UC Megwalu","year":"2022","unstructured":"Megwalu UC, Moon PK (2022) Thyroid cancer incidence and mortality trends in the United States: 2000\u20132018. Thyroid 32:560\u2013570","journal-title":"Thyroid"},{"key":"2053_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SA Jr (2016) Biologic and clinical perspectives on thyroid cancer. N Engl J Med 375:1054\u20131067","journal-title":"N Engl J Med"},{"key":"2053_CR4","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"Lim H, Devesa SS, Sosa JA et al (2017) Trends in thyroid cancer incidence and mortality in the United States, 1974\u20132013. JAMA 317:1338\u20131348","journal-title":"JAMA"},{"key":"2053_CR5","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E et al (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892\u20132899","journal-title":"J Clin Endocrinol Metab"},{"key":"2053_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1590\/2359-3997000000245","volume":"61","author":"A Schmidt","year":"2017","unstructured":"Schmidt A, Iglesias L, Klain M et al (2017) Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation. Arch Endocrinol Metab 61:81\u201389","journal-title":"Arch Endocrinol Metab"},{"key":"2053_CR7","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL et al (2021) (177)Lu-dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22:1752\u20131763","journal-title":"Lancet Oncol"},{"key":"2053_CR8","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S et al (2024) (177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 403:2807\u20132817","journal-title":"Lancet"},{"key":"2053_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3413\/Nukmed-0646-14-02","volume":"53","author":"S Woelfl","year":"2014","unstructured":"Woelfl S, Bogner S, Huber H et al (2014) Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies. Nuklearmedizin 53:179\u2013185","journal-title":"Nuklearmedizin"},{"issue":"3","key":"2053_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Sch\u00e4r JC, Waser B et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3):273\u2013282","journal-title":"Eur J Nucl Med"},{"key":"2053_CR11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s00259-024-06944-y","volume":"52","author":"SC Kunte","year":"2025","unstructured":"Kunte SC, Wenter V, Toms J et al (2025) PET\/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [(18)F]SiTATE - first clinical experiences. Eur J Nucl Med Mol Imaging 52:900\u2013912","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2053_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1089\/thy.2013.0225","volume":"24","author":"A Versari","year":"2014","unstructured":"Versari A, Sollini M, Frasoldati A et al (2014) Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid 24:715\u2013726","journal-title":"Thyroid"},{"key":"2053_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.4103\/ijnm.IJNM_37_17","volume":"32","author":"A Sood","year":"2017","unstructured":"Sood A, Singh H, Sood A et al (2017) Incidentally detected thyroid follicular neoplasm on somatostatin receptor imaging and post-therapy scan. Indian J Nucl Med 32:224\u2013226","journal-title":"Indian J Nucl Med"},{"key":"2053_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100332","volume":"36","author":"A Gillis","year":"2023","unstructured":"Gillis A, Zheng-Pywell R, McLeod C et al (2023) Somatostatin receptor type 2 and thyroid-stimulating hormone receptor expression in oncocytic thyroid neoplasms: implications for prognosis and treatment. Mod Pathol 36:100332","journal-title":"Mod Pathol"},{"key":"2053_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hed.26024","volume":"42","author":"RV Parghane","year":"2020","unstructured":"Parghane RV, Naik C, Talole S et al (2020) Clinical utility of (177) Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. Head Neck 42:401\u2013416","journal-title":"Head Neck"},{"issue":"3","key":"2053_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1055\/a-1650-9762","volume":"61","author":"F Eilsberger","year":"2022","unstructured":"Eilsberger F, Kreissl MC, Luster M, Pfestroff A (2022) Therapiekonzepte beim Schilddr\u00fcsenkarzinom [Therapy concepts for thyroid carcinoma]. Nuklearmedizin. 61(3):223\u2013230","journal-title":"Nuklearmedizin."},{"issue":"Suppl 2","key":"2053_CR17","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","volume":"10","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, de Jong M, Kooij PP et al (1999) Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10(Suppl 2):S23-29","journal-title":"Ann Oncol"},{"key":"2053_CR18","first-page":"39","volume":"4","author":"H Budiawan","year":"2013","unstructured":"Budiawan H, Salavati A, Kulkarni HR et al (2013) Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging 4:39\u201352","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"2053_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113507","author":"E Grossrubatscher","year":"2020","unstructured":"Grossrubatscher E, Fanciulli G, Pes L et al (2020) Advances in the management of medullary thyroid carcinoma: focus on peptide receptor radionuclide therapy. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9113507","journal-title":"J Clin Med"},{"key":"2053_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.semnuclmed.2016.01.010","volume":"46","author":"A Salavati","year":"2016","unstructured":"Salavati A, Puranik A, Kulkarni HR et al (2016) Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues. Semin Nucl Med 46:215\u2013224","journal-title":"Semin Nucl Med"},{"key":"2053_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.nucmedbio.2014.12.006","volume":"42","author":"C Lapa","year":"2015","unstructured":"Lapa C, Werner RA, Schmid JS et al (2015) Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. Nucl Med Biol 42:349\u2013354","journal-title":"Nucl Med Biol"},{"key":"2053_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/1874471012666190110170623","volume":"12","author":"A Revy","year":"2019","unstructured":"Revy A, Hallouard F, Joyeux-Klamber S et al (2019) Feasibility and evaluation of automated methods for radiolabeling of radiopharmaceutical kits with Gallium-68. Curr Radiopharm 12:229\u2013237","journal-title":"Curr Radiopharm"},{"key":"2053_CR23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00259-019-04501-6","volume":"47","author":"H Ilhan","year":"2020","unstructured":"Ilhan H, Lindner S, Todica A et al (2020) Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging 47:870\u2013880","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2053_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00259-004-1702-y","volume":"32","author":"WA Breeman","year":"2005","unstructured":"Breeman WA, de Jong M, de Blois E et al (2005) Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 32:478\u2013485","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2053_CR25","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1007\/s00259-021-05351-x","volume":"48","author":"L Beyer","year":"2021","unstructured":"Beyer L, Gosewisch A, Lindner S et al (2021) Dosimetry and optimal scan time of [18F]SiTATE-PET\/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 48:3571\u20133581","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2053_CR26","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1021\/bc100316c","volume":"21","author":"C W\u00e4ngler","year":"2010","unstructured":"W\u00e4ngler C, Waser B, Alke A et al (2010) One-step 1\u2078F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET). Bioconjug Chem 21:2289\u20132296","journal-title":"Bioconjug Chem"},{"key":"2053_CR27","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1002\/anie.200600795","volume":"45","author":"R Schirrmacher","year":"2006","unstructured":"Schirrmacher R, Bradtm\u00f6ller G, Schirrmacher E et al (2006) 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor. Angew Chem Int Ed Engl 45:6047\u20136050","journal-title":"Angew Chem Int Ed Engl"},{"key":"2053_CR28","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00259-003-1142-0","volume":"30","author":"WA Breeman","year":"2003","unstructured":"Breeman WA, De Jong M, Visser TJ et al (2003) Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 30:917\u2013920","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2053_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5603\/NMR.2014.0022","volume":"17","author":"A d'Amico","year":"2014","unstructured":"d\u2019Amico A, Gorczewska I, Gorczewski K et al (2014) Effect of furosemide administration before F-18 fluorodeoxyglucose positron emission tomography\/computed tomography on urine radioactivity and detection of uterine cervical cancer. Nucl Med Rev Cent East Eur 17:83\u201386","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"2053_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","volume":"146","author":"V Ambrosini","year":"2021","unstructured":"Ambrosini V, Kunikowska J, Baudin E et al (2021) Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 146:56\u201373","journal-title":"Eur J Cancer"},{"key":"2053_CR31","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/RLU.0000000000004239","volume":"47","author":"A Weich","year":"2022","unstructured":"Weich A, Werner RA, Serfling SE et al (2022) Rechallenge with additional doses of 177Lu-DOTATOC after failure of maintenance therapy with cold somatostatin analogs. Clin Nucl Med 47:719\u2013720","journal-title":"Clin Nucl Med"},{"issue":"4","key":"2053_CR32","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/pharmaceutics15041110","volume":"15","author":"L Urso","year":"2023","unstructured":"Urso L, Nieri A, Uccelli L et al (2023) Lutathera\u00ae orphans: state of the art and future application of radioligand therapy with 177Lu-DOTATATE. Pharmaceutics. 15(4):1110","journal-title":"Pharmaceutics."},{"key":"2053_CR33","unstructured":"Novartis (2020)\u00a0Fachinformation Lutathera. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200401147483\/anx_147483_de.pdf.\u00a0Accessed 12.12.2024"},{"key":"2053_CR34","unstructured":"U.S. Department of Health and Human Services\u00a0(2017) Common terminology criteria for adverse events (CTCAE). https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf.\u00a0Accessed 18.09.2025"},{"issue":"9","key":"2053_CR35","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3390\/cancers11091382","volume":"11","author":"M Aashiq","year":"2019","unstructured":"Aashiq M, Silverman DA, Na\u2019ara S, Takahashi H, Amit M (2019) Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies. Cancers (Basel) 11(9):1382","journal-title":"Cancers (Basel)"},{"key":"2053_CR36","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J et al (2020) Semiautomatically quantified tumor volume using (68)Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med 61:1786\u20131792","journal-title":"J Nucl Med"},{"key":"2053_CR37","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","volume":"45","author":"AK Seitz","year":"2018","unstructured":"Seitz AK, Rauscher I, Haller B et al (2018) Preliminary results on response assessment using (68)Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging 45:602\u2013612","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2053_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"2053_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.861434","volume":"13","author":"G Puliani","year":"2022","unstructured":"Puliani G, Chiefari A, Mormando M et al (2022) New insights in PRRT: lessons from 2021. Front Endocrinol (Lausanne) 13:861434","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2053_CR40","doi-asserted-by":"crossref","unstructured":"Hertelendi M, Belguenani O, Cherfi A, Folitar I, Kollar G, Polack BD (2023) Efficacy and safety of [177Lu]Lu-DOTA-TATE in adults with inoperable or metastatic somatostatin receptor-positive pheochromocytomas\/paragangliomas, bronchial and unknown origin neuroendocrine tumors, and medullary thyroid carcinoma: A systematic literature review. Biomedicines. 2023;11(4):1024","DOI":"10.3390\/biomedicines11041024"},{"key":"2053_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/RLU.0000000000004539","volume":"48","author":"Q Liu","year":"2023","unstructured":"Liu Q, Kulkarni HR, Zhao T et al (2023) Peptide receptor radionuclide therapy in patients with advanced progressive medullary thyroid cancer: efficacy, safety, and survival predictors. Clin Nucl Med 48:221\u2013227","journal-title":"Clin Nucl Med"},{"key":"2053_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.929391","volume":"13","author":"M Opali\u0144ska","year":"2022","unstructured":"Opali\u0144ska M, Morawiec-S\u0142awek K, Kania-Kuc A et al (2022) Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET\/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors. Front Endocrinol (Lausanne) 13:929391","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2053_CR43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.37349\/etat.2023.00153","volume":"4","author":"AK Jha","year":"2023","unstructured":"Jha AK, Mithun S, Sherkhane UB et al (2023) Emerging role of quantitative imaging (radiomics) and artificial intelligence in precision oncology. Explor Target Antitumor Ther 4:569\u2013582","journal-title":"Explor Target Antitumor Ther"},{"key":"2053_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1530507","volume":"14","author":"T Qiao","year":"2024","unstructured":"Qiao T, Cheng Z, Duan Y (2024) Innovative applications and future trends of multiparametric PET in the assessment of immunotherapy efficacy. Front Oncol 14:1530507","journal-title":"Front Oncol"},{"key":"2053_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymeth.2020.05.022","volume":"188","author":"A Ibrahim","year":"2021","unstructured":"Ibrahim A, Primakov S, Beuque M et al (2021) Radiomics for precision medicine: current challenges, future prospects, and the proposal of a new framework. Methods 188:20\u201329","journal-title":"Methods"},{"key":"2053_CR46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12885-021-08257-x","volume":"21","author":"Z Maghsoomi","year":"2021","unstructured":"Maghsoomi Z, Emami Z, Malboosbaf R et al (2021) Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer 21:579","journal-title":"BMC Cancer"},{"key":"2053_CR47","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1089\/thy.2021.0091","volume":"31","author":"VF Koehler","year":"2021","unstructured":"Koehler VF, Berg E, Adam P et al (2021) Real-world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. Thyroid 31:1531\u20131541","journal-title":"Thyroid"},{"key":"2053_CR48","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000514182","volume":"10","author":"L Valerio","year":"2021","unstructured":"Valerio L, Giani C, Agate L et al (2021) Prevalence and risk factors of developing fistula or organ perforation in patients treated with Lenvatinib for radioiodine-refractory thyroid cancer. Eur Thyroid J 10:399\u2013407","journal-title":"Eur Thyroid J"},{"key":"2053_CR49","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3803\/EnM.2022.1553","volume":"37","author":"CK Jung","year":"2022","unstructured":"Jung CK, Bychkov A, Kakudo K (2022) Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach. Endocrinol Metab 37:703\u2013718","journal-title":"Endocrinol Metab"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02053-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-02053-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02053-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:02:34Z","timestamp":1768413754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-02053-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2053"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-02053-w","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The analysis was performed in compliance with the principles of the Declaration of Helsinki and was approved by the institutional ethics committee of the Ludwig-Maximilians-University of Munich (IRB #21\u20130102 and #24\u20130982).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Waved by the ethics board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"AH: Personal fees from ABX advanced biochemical compounds outside the submitted work. RAW: speaker honoraria from Novartis\/AAA and PentixaPharm, advisory board work for Novartis\/AAA and Bayer. MJZ: speaker honoraria from Novartis, SIRTEX and Terumo, advisory board for Boston Scientific.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}